Does the media favor NAMS or CGEM?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 2 mentions for NewAmsterdam Pharma. Cullinan Therapeutics' average media sentiment score of 0.18 beat NewAmsterdam Pharma's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CGEM or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is CGEM or VKTX more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Viking Therapeutics N/A -71.31% -65.35%

Does the media prefer CGEM or VKTX?

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 4 articles in the media. Viking Therapeutics' average media sentiment score of 0.19 beat Cullinan Therapeutics' score of 0.18 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRNX or CGEM?

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 4 mentions for Cullinan Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.33 beat Cullinan Therapeutics' score of 0.18 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cullinan Therapeutics (CGEM) Competitors

$12.57 -0.94 (-6.94%)

As of 09:55 AM Eastern

Compare

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include NewAmsterdam Pharma (NAMS), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NewAmsterdam Pharma currently has a consensus price target of $48.60, indicating a potential upside of 54.31%. Cullinan Therapeutics has a consensus price target of $30.75, indicating a potential upside of 144.59%. Given Cullinan Therapeutics' higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Cullinan Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 2 mentions for NewAmsterdam Pharma. Cullinan Therapeutics' average media sentiment score of 0.18 beat NewAmsterdam Pharma's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has higher revenue and earnings than Cullinan Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	163.64	-$203.82M	-$1.79	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

NewAmsterdam Pharma beats Cullinan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Cullinan Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Cullinan Therapeutics had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 0.18 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Cullinan Therapeutics	Neutral

Catalyst Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.50	$214.33M	$1.74	17.98
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 2.29%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 144.59%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Catalyst Pharmaceuticals beats Cullinan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 4 articles in the media. Viking Therapeutics' average media sentiment score of 0.19 beat Cullinan Therapeutics' score of 0.18 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $30.75, suggesting a potential upside of 144.59%. Viking Therapeutics has a consensus target price of $93.60, suggesting a potential upside of 227.75%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Cullinan Therapeutics beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Cullinan Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 4 mentions for Cullinan Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.33 beat Cullinan Therapeutics' score of 0.18 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cullinan Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$18.07M	193.79	-$465.32M	-$5.13	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals presently has a consensus target price of $76.13, indicating a potential upside of 129.23%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 144.59%. Given Cullinan Therapeutics' higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Summary

Crinetics Pharmaceuticals beats Cullinan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Cullinan Therapeutics (NASDAQ:CGEM) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.54 beat Cullinan Therapeutics' score of 0.18 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Cullinan Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Kiniksa Pharmaceuticals International	$754.05M	4.94	$59.01M	$0.90	53.80

Cullinan Therapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Cullinan Therapeutics currently has a consensus price target of $30.75, indicating a potential upside of 144.59%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 25.69%. Given Cullinan Therapeutics' higher possible upside, equities analysts plainly believe Cullinan Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Cullinan Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$772.68M	$3.33B	$6.46B	$11.98B
Dividend Yield	N/A	2.31%	2.67%	5.55%
P/E Ratio	-3.74	19.02	23.90	23.62
Price / Sales	N/A	179.19	483.49	89.64
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.82	7.97	10.34	6.66
Net Income	-$219.88M	$23.89M	$3.57B	$337.72M
7 Day Performance	-22.44%	-5.14%	-0.93%	-3.74%
1 Month Performance	-13.59%	2.54%	3.54%	0.95%
1 Year Performance	38.46%	36.80%	23.79%	25.35%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.0814 of 5 stars	$12.57 -6.9%	$30.75 +144.6%	+48.8%	$772.68M	N/A	N/A	30	Analyst Downgrade Gap Up
NAMS NewAmsterdam Pharma	2.8349 of 5 stars	$31.68 -6.0%	$48.00 +51.5%	+56.5%	$3.94B	$22.50M	N/A	4
CPRX Catalyst Pharmaceuticals	3.5967 of 5 stars	$31.28 +0.1%	$32.00 +2.3%	+20.9%	$3.82B	$588.99M	17.97	80	Positive News
VKTX Viking Therapeutics	3.4016 of 5 stars	$29.70 -9.3%	$93.60 +215.2%	+2.2%	$3.80B	N/A	N/A	20	Gap Up
CRNX Crinetics Pharmaceuticals	3.2807 of 5 stars	$33.10 -6.9%	$76.13 +130.0%	-0.3%	$3.75B	$18.07M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Do institutionals & insiders believe in NAMS or CGEM?

Do analysts prefer NAMS or CGEM?

Which has more volatility and risk, NAMS or CGEM?

Is NAMS or CGEM more profitable?

Does the media favor NAMS or CGEM?

Which has better earnings & valuation, NAMS or CGEM?

Summary

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Is CPRX or CGEM more profitable?

Does the media refer more to CPRX or CGEM?

Which has better earnings & valuation, CPRX or CGEM?

Which has more risk & volatility, CPRX or CGEM?

Do institutionals & insiders believe in CPRX or CGEM?

Do analysts prefer CPRX or CGEM?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Is CGEM or VKTX more profitable?

Does the media prefer CGEM or VKTX?

Which has better valuation and earnings, CGEM or VKTX?

Do institutionals & insiders hold more shares of CGEM or VKTX?

Which has more volatility & risk, CGEM or VKTX?

Do analysts recommend CGEM or VKTX?

Summary

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Is CRNX or CGEM more profitable?

Does the media favor CRNX or CGEM?

Which has stronger valuation & earnings, CRNX or CGEM?

Do institutionals and insiders have more ownership in CRNX or CGEM?

Do analysts prefer CRNX or CGEM?

Which has more volatility & risk, CRNX or CGEM?

Summary

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Does the media refer more to CGEM or KNSA?

Is CGEM or KNSA more profitable?

Which has higher valuation and earnings, CGEM or KNSA?

Which has more volatility & risk, CGEM or KNSA?

Do analysts recommend CGEM or KNSA?

Do institutionals & insiders believe in CGEM or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools